{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:33:14Z","timestamp":1790757194948,"version":"4.1.0"},"reference-count":29,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2014,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Fidaxomicin (FDX) is a narrow-spectrum antibiotic for the treatment of\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Clostridium difficile<\/jats:named-content>\n            -associated diarrhea. While FDX and rifamycins share the same target (RNA polymerase), FDX exhibits a unique mode of action distinct from that of rifamycins. In comparative microbiological studies with\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">C. difficile<\/jats:named-content>\n            , FDX interacted synergistically with rifamycins, demonstrated a lower propensity for the development of resistance to rifamycins, and exhibited no cross-resistance with rifamycins. These results highlight differences in the mechanisms of action of FDX and rifamycins.\n          <\/jats:p>","DOI":"10.1128\/aac.02572-13","type":"journal-article","created":{"date-parts":[[2014,2,19]],"date-time":"2014-02-19T05:16:41Z","timestamp":1392787001000},"page":"2934-2937","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":32,"title":["Comparative Microbiological Studies of Transcription Inhibitors Fidaxomicin and the Rifamycins in Clostridium difficile"],"prefix":"10.1128","volume":"58","author":[{"given":"Farah","family":"Babakhani","sequence":"first","affiliation":[{"name":"Optimer Pharmaceuticals, Inc., San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Seddon","sequence":"additional","affiliation":[{"name":"Optimer Pharmaceuticals, Inc., San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Sears","sequence":"additional","affiliation":[{"name":"Optimer Pharmaceuticals, Inc., San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis358"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2005.07.014"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04296.x"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1586\/eri.10.58"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.8.2205-2206.2000"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr377"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1086\/511870"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.anaerobe.2009.08.004"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1086\/596315"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0910812"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(11)70374-7"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis337"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01443-07"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1099\/mic.0.042010-0"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.11.4430-4434.2004"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.12.4898-4902.2004"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01623-06"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.029470-0"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00104-11"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis453"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks450"},{"key":"e_1_3_2_23_2","first-page":"330","volume-title":"Antibiotics in laboratory medicine","author":"Eliopoulos GM","year":"1996","unstructured":"EliopoulosGMMoelleringRCJr. 1996. Antimicrobial combinations, p 330\u2013396. In LorianV (ed), Antibiotics in laboratory medicine, 4th ed. Williams & Wilkins Co., Baltimore, MD.","edition":"4"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.05100-11"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00342-08"},{"key":"e_1_3_2_26_2","volume-title":"Presented at 23rd European Society of Clinical Microbiology and Infectious Diseases","author":"Kuehne SA","year":"2013","unstructured":"KuehneSADempsterAWHeegDLongshawCMintonNP. 2013. Use of allelic exchange to characterize the impact of rpoB\/C mutations on fitness of Clostridium difficile and sensitivity to fidaxomicin. Presented at 23rd European Society of Clinical Microbiology and Infectious Diseases, Berlin, Germany, 23 to 30 April 2013."},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis339"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00625-11"},{"key":"e_1_3_2_29_2","volume-title":"Methods of antimicrobial susceptibility testing of anaerobic bacteria; approved standards","author":"Clinical and Laboratory Standards Institute","year":"2007","unstructured":"Clinical and Laboratory Standards Institute. 2007. Methods of antimicrobial susceptibility testing of anaerobic bacteria; approved standards, seventh edition. CLSI M11-A7. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_30_2","volume-title":"Performance standards for antimicrobial susceptibility testing, 20th informational supplement","author":"Clinical and Laboratory Standards Institute","year":"2010","unstructured":"Clinical and Laboratory Standards Institute. 2010. Performance standards for antimicrobial susceptibility testing, 20th informational supplement. CLSI M100-S20. Clinical and Laboratory Standards Institute, Wayne, PA."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02572-13","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02572-13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:40:42Z","timestamp":1645483242000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02572-13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["10.1128\/AAC.02572-13"],"URL":"https:\/\/doi.org\/10.1128\/aac.02572-13","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"2013-11-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-02-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-04-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}